Brought to you by 
Vivus grants Menarini marketing rights to Spedra in Europe, Australia, and New Zealand
07 Oct 2016
Executive Summary
Menarini Group has received rights to market Vivus Inc.’s (focused on sexual health and metabolic and respiratory conditions) Spedra (avanafil) in over 40 European countries, Australia, and New Zealand. Spedra is a phosphodiesterase-5 inhibitor that was approved in the US in early 2012 (as Stendra) and in Europe last month for erectile dysfunction.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Manufacturing or Supply
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vivus grants Menarini marketing rights to Spedra in Europe, Australia, and New Zealand
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice